You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort
|
|---|---|
| Published in |
Alzheimer's Research & Therapy, February 2015
|
| DOI | 10.1186/s13195-015-0105-6 |
| Pubmed ID | |
| Authors |
Veer B Gupta, Andrea C Wilson, Samantha Burnham, Eugene Hone, Steve Pedrini, Simon M Laws, Wei Ling Florence Lim, Alan Rembach, Stephanie Rainey-Smith, David Ames, Lynne Cobiac, S Lance Macaulay, Colin L Masters, Christopher C Rowe, Ashley I Bush, Ralph N Martins, for the AIBL Research Group |
| Abstract |
Alzheimer's disease (AD) is a growing socioeconomic problem worldwide. Early diagnosis and prevention of this devastating disease have become a research priority. Consequently, the identification of clinically significant and sensitive blood biomarkers for its early detection is very important. Apolipoprotein E (APOE) is a well-known and established genetic risk factor for late-onset AD; however, the impact of the protein level on AD risk is unclear. We assessed the utility of plasma ApoE protein as a potential biomarker of AD in the large, well-characterised Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL) cohort. Total plasma ApoE levels were measured at 18-month follow-up using a commercial bead-based enzyme-linked immunosorbent assay: the Luminex xMAP human apolipoprotein kit. ApoE levels were then analysed between clinical classifications (healthy controls, mild cognitive impairment (MCI) and AD) and correlated with the data available from the AIBL cohort, including but not limited to APOE genotype and cerebral amyloid burden. A significant decrease in ApoE levels was found in the AD group compared with the healthy controls. These results validate previously published ApoE protein levels at baseline obtained using different methodology. ApoE protein levels were also significantly affected, depending on APOE genotypes, with ε2/ε2 having the highest protein levels and ε4/ε4 having the lowest. Plasma ApoE levels were significantly negatively correlated with cerebral amyloid burden as measured by neuroimaging. ApoE is decreased in individuals with AD compared with healthy controls at 18-month follow-up, and this trend is consistent with our results published at baseline. The influence of APOE genotype and sex on the protein levels are also explored. It is clear that ApoE is a strong player in the aetiology of this disease at both the protein and genetic levels. |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Netherlands | 1 | 2% |
| United States | 1 | 2% |
| Unknown | 58 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 16% |
| Researcher | 10 | 16% |
| Other | 5 | 8% |
| Student > Postgraduate | 4 | 7% |
| Student > Master | 3 | 5% |
| Other | 11 | 18% |
| Unknown | 18 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Neuroscience | 10 | 16% |
| Agricultural and Biological Sciences | 7 | 11% |
| Medicine and Dentistry | 7 | 11% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Chemistry | 2 | 3% |
| Other | 12 | 20% |
| Unknown | 20 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 April 2015.
All research outputs
#4,172,977
of 22,799,071 outputs
Outputs from Alzheimer's Research & Therapy
#905
of 1,220 outputs
Outputs of similar age
#51,084
of 254,697 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#12
of 25 outputs
Altmetric has tracked 22,799,071 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,220 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.1. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 254,697 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.